TY - JOUR
T1 - Glioblastoma stem-like cells
T2 - Characteristics, microenvironment, and therapy
AU - Yi, Yang
AU - Hsieh, I. Yun
AU - Huang, Xiaojia
AU - Li, Jie
AU - Zhao, Wei
N1 - Funding Information:
We thank Dr. Jingxin Mo and Miss. Bin Lu for valuable suggestions. This work was supported by National Science Foundation of China (No. 81572766) and SYSU Young Teachers Training Program (No. 16YKZD14).
Publisher Copyright:
© 2016 Yi, Hsieh, Huang, Li and Zhao.
PY - 2016
Y1 - 2016
N2 - Glioblastoma multiforme (GBM), grade IV astrocytoma, is the most fatal malignant primary brain tumor. GBM contains functional subsets of cells called glioblastoma stem-like cells (GSCs), which are radioresistant and chemoresistant and eventually lead to tumor recurrence. Recent studies showed that GSCs reside in particular tumor niches that are necessary to support their behavior. To successfully eradicate GBM growth and recurrence, new strategies selectively targeting GSCs and/or their microenvironmental niche should be designed. In this regard, here we focus on elucidating the molecular mechanisms that govern these GSC properties and on understanding the mechanism of the microenvironmental signals within the tumor mass. Moreover, to overcome the blood-brain barrier, which represents a critical limitation of GBM treatments, a new drug delivery system should be developed. Nanoparticles can be easily modified by different methods to facilitate delivery efficiency of chemotherapeutics, to enhance the accumulation within the tumors, and to promote the capacity for targeting the GSCs. Therefore, nanotechnology has become the most promising approach to GSC-targeting therapy. Additionally, we discussed the future of nanotechnology-based targeted therapy and point out the disadvantages that should be overcome.
AB - Glioblastoma multiforme (GBM), grade IV astrocytoma, is the most fatal malignant primary brain tumor. GBM contains functional subsets of cells called glioblastoma stem-like cells (GSCs), which are radioresistant and chemoresistant and eventually lead to tumor recurrence. Recent studies showed that GSCs reside in particular tumor niches that are necessary to support their behavior. To successfully eradicate GBM growth and recurrence, new strategies selectively targeting GSCs and/or their microenvironmental niche should be designed. In this regard, here we focus on elucidating the molecular mechanisms that govern these GSC properties and on understanding the mechanism of the microenvironmental signals within the tumor mass. Moreover, to overcome the blood-brain barrier, which represents a critical limitation of GBM treatments, a new drug delivery system should be developed. Nanoparticles can be easily modified by different methods to facilitate delivery efficiency of chemotherapeutics, to enhance the accumulation within the tumors, and to promote the capacity for targeting the GSCs. Therefore, nanotechnology has become the most promising approach to GSC-targeting therapy. Additionally, we discussed the future of nanotechnology-based targeted therapy and point out the disadvantages that should be overcome.
KW - Epigenetic plasticity
KW - Glioblastoma stem-like cells
KW - Nanocarrier technologies
KW - Nanoparticle
KW - Tumor microenvironment
UR - http://www.scopus.com/inward/record.url?scp=85009165863&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85009165863&partnerID=8YFLogxK
U2 - 10.3389/fphar.2016.00477
DO - 10.3389/fphar.2016.00477
M3 - Review article
C2 - 28003805
AN - SCOPUS:85009165863
SN - 1663-9812
VL - 7
JO - Frontiers in Pharmacology
JF - Frontiers in Pharmacology
IS - DEC
M1 - 477
ER -